Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

786 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P. Wei AH, et al. Among authors: bergeron j. Blood. 2020 Jun 11;135(24):2137-2145. doi: 10.1182/blood.2020004856. Blood. 2020. PMID: 32219442 Free PMC article. Clinical Trial.
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).
Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens DA, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, DiNardo CD. Wei AH, et al. Among authors: bergeron j. Blood Cancer J. 2021 Oct 1;11(10):163. doi: 10.1038/s41408-021-00555-8. Blood Cancer J. 2021. PMID: 34599139 Free PMC article. Clinical Trial.
Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy.
Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens DA, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, DiNardo CD. Wei AH, et al. Among authors: bergeron j. Blood Cancer J. 2021 Oct 26;11(10):171. doi: 10.1038/s41408-021-00565-6. Blood Cancer J. 2021. PMID: 34702803 Free PMC article. No abstract available.
Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.
Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Jiang Q, Sun Y, Chyla B, Mendes W, DiNardo CD. Wei AH, et al. Among authors: bergeron j. Blood. 2022 Dec 22;140(25):2754-2756. doi: 10.1182/blood.2022016963. Blood. 2022. PMID: 36112968 Free article. No abstract available.
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Kantarjian H, et al. Among authors: bergeron j. N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783. N Engl J Med. 2017. PMID: 28249141 Free PMC article. Clinical Trial.
Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs.
Bergeron J, Clappier E, Radford I, Buzyn A, Millien C, Soler G, Ballerini P, Thomas X, Soulier J, Dombret H, Macintyre EA, Asnafi V. Bergeron J, et al. Blood. 2007 Oct 1;110(7):2324-30. doi: 10.1182/blood-2007-04-079988. Epub 2007 Jul 3. Blood. 2007. PMID: 17609427 Free article.
Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission.
Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, Hamadani M, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ; Acute Leukemia Committee of the CIBMTR and the Dana Farber ALL Consortium. Seftel MD, et al. Among authors: bergeron j. Am J Hematol. 2016 Mar;91(3):322-9. doi: 10.1002/ajh.24285. Am J Hematol. 2016. PMID: 26701142 Free PMC article.
Extensive molecular mapping of TCRα/δ- and TCRβ-involved chromosomal translocations reveals distinct mechanisms of oncogene activation in T-ALL.
Le Noir S, Ben Abdelali R, Lelorch M, Bergeron J, Sungalee S, Payet-Bornet D, Villarèse P, Petit A, Callens C, Lhermitte L, Baranger L, Radford-Weiss I, Grégoire MJ, Dombret H, Ifrah N, Spicuglia S, Romana S, Soulier J, Nadel B, Macintyre E, Asnafi V. Le Noir S, et al. Among authors: bergeron j. Blood. 2012 Oct 18;120(16):3298-309. doi: 10.1182/blood-2012-04-425488. Epub 2012 Sep 4. Blood. 2012. PMID: 22948044 Free article.
A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.
Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, Miller WH Jr, Borden KL. Assouline S, et al. Among authors: bergeron j. Haematologica. 2015 Jan;100(1):e7-9. doi: 10.3324/haematol.2014.111245. Epub 2014 Nov 25. Haematologica. 2015. PMID: 25425688 Free PMC article. Clinical Trial. No abstract available.
786 results